Indaptus Therapeutics, Inc. (INDP)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Indaptus Therapeutics, Inc. (INDP) is up 29.7% since the beginning of the year. At $4 per share, INDP is trading 71.9% below its 52-week high of $13. Investors who bought $1,000 worth of INDP shares 5 years ago would now be looking at an investment worth $9.

Indaptus Therapeutics, Inc. (INDP) has returned 29.73% so far this year and -50.08% over the past 12 months. Over the last ten years, INDP has returned -54.66% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Aug 4, 2015, INDP's average daily return is -0.07%, while the average monthly return is -2.75%.

Historically, 39% of months were positive and 61% were negative. The best month was Jun 2026 with a return of +114.5%, while the worst month was Jul 2019 at -89.0%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 15 months.

On a daily basis, INDP closed higher 43% of trading days. The best single day was Jun 4, 2026 with a return of +114.9%, while the worst single day was Jul 22, 2019 at -81.6%.

Indaptus Therapeutics, Inc. has an annualized alpha of -26.62%, beta of 1.08, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since August 04, 2015.

• This stock participated in 162.08% of S&P 500 Index downside but only -96.83% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

INDP ranks 39 for risk / return — below 39% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Indaptus Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Indaptus Therapeutics, Inc. was 100.00%, occurring on May 21, 2026. The portfolio has not yet recovered.

The current Indaptus Therapeutics, Inc. drawdown is 99.98%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Indaptus Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Indaptus Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.